Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-ΚB transcription factors

Journal of Antimicrobial Chemotherapy

Volumn 49, Issue 5, 2002, Pages 745-755

  Kikuchi, Tohru ^a   Hagiwara, Koichi ^a   Honda, Yoshihiro ^b   Gomi, Kazunori ^a   Kobayashi, Takao ^a   Takahashi, Hiroshi ^a   Tokue, Yutaka ^a   Watanabe, Akira ^a   Nukiwa, Toshihiro ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b SENDAI KOUSEI HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; BACTERIUM LIPOPOLYSACCHARIDE; CLARITHROMYCIN; ERYTHROMYCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; LUCIFERASE; MACROLIDE; TRANSCRIPTION FACTOR AP 1; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; LIPOPOLYSACCHARIDE; MESSENGER RNA; NUCLEAR PROTEIN;

AMINO ACID SEQUENCE; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOASSAY; BRONCHIOLITIS; CHRONIC GASTRITIS; CHRONIC SINUSITIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; ESCHERICHIA COLI; GEL MOBILITY SHIFT ASSAY; GENE CONTROL; GENE DELETION; GENE EXPRESSION; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATORY DISEASE; LEUKEMIA CELL LINE; MONOCYTE; PLASMID; PROMOTER REGION; PROTEIN BINDING; PSEUDOMONAS AERUGINOSA; REPORTER GENE; RESPIRATORY TRACT DISEASE; ACUTE MONOCYTIC LEUKEMIA; BIOSYNTHESIS; CELL CULTURE; CHEMICAL PHENOMENA; DRUG ANTAGONISM; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

ANTIBIOTICS, MACROLIDE; CLARITHROMYCIN; DEPRESSION, CHEMICAL; ESCHERICHIA COLI; HUMAN; INDICATORS AND REAGENTS; INTERLEUKIN-8; LEUKEMIA, MONOCYTIC, ACUTE; LIPOPOLYSACCHARIDES; LUCIFERASE; MONOCYTES; NF-KAPPA B; NUCLEAR PROTEINS; PLASMIDS; RNA, MESSENGER; SUPPORT, NON-U.S. GOV'T; TRANSCRIPTION FACTOR AP-1; TRANSFECTION; TUMOR CELLS, CULTURED; ANTI-BACTERIAL AGENTS; HUMANS; LUCIFERASES;

EID: 0036001168     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Erythromycin inhibition of lipopolysaccharide-stimulated tumor necrosis factor alpha production by human monocytes in vitro
2. Long-term azithromycin may improve lung function in children with cystic fibrosis
3. Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8, and sICAM-1 by cultured human bronchial epithelial cells
4. Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma
5. Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases
6. Interleukin-1 beta, tumor necrosis factor-alpha, and interleukin-8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: A potential mechanism of macrolide therapy
7. Erythromycin suppresses interleukin-6 expression by human bronchial epithelial cells; a potential mechanism of its antiinflammatory action
8. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells
9. Clinical effect of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis
10. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin
11. Long-term low dose administration of erythromycin to patients with diffuse panbronchiolitis
12. Recognition of Gram-negative bacteria and endotoxin by the innate immune system
13. Neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leukocytes: Partial characterization and separation from interleukin-1 (IL-1)
14. A novel neutrophil-activating factor produced by human mononuclear phagocytes
15. Adhesion of flowing neutrophils to cultured endothelial cells after hypoxia and reoxygenation in vitro
16. Interleukin-8-induced transcellular neutrophil migration is facilitated by endothelial and pulmonary epithelial cells
17. Human granulocyte chemotactic peptide (IL-8) as a specific neutrophil degranulator: Comparison with other monokines
18. A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis
19. Interleukin-8: An important chemoattractant in sputum of patients with chronic inflammatory airway diseases
20. Gastric interleukin-8 and IgA IL-8 autoantibodies in Helicobacter pylori infection
21. Microbes and microbial toxins: Paradigms for microbial mucosal interactions. IV. Helicobacter pylori strain-specific activation of signal transduction cascades related to gastric inflammation
22. Chemokine expression in Helicobacter pylori-infected gastric mucosa
23. The anti-inflammatory effect of erythromycin and its derivatives, with special reference to nasal polyposis and chronic sinusitis
24. An open trial of oral macrolide treatment of psoriasis vulgaris
25. Therapeutic effects of macrolides on patients with palmoplantar pustulosis
26. Neutrophil-activating peptide-1/interleukin-8, a novel cytokine that activates neutrophils
27. Molecular analysis of the inhibition of interleukin-8 production by dexamethasone in a human fibrosarcoma cell line
28. Novel mechanism of glucocorticoid-mediated gene repression: Nuclear factor-κB is target of glucocorticoid-mediated interleukin-8 gene repression
29. The interleukin-8 AP-1 and κB-like sites are genetic end targets of FK506-sensitive pathway accompanied by calcium mobilization
30. Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells
31. Erythromycin suppresses nuclear factor-kappa B and activator protein-1 activation in human bronchial epithelial cells
32. Toll-like receptors: Critical proteins linking innate and acquired immunity
33. Interleukin-8 gene expression in human bronchial epithelial cells
34. Construction of a lipopolysaccharide reporter cell line and its use in identifying mutants defective in endotoxin, but not TNF-alpha, signal transduction
35. Antibody supershift assay
36. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: The MACH I study
37. The MACH 2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies